U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H18N3O5S.Na
Molecular Weight 387.386
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMOXICILLIN SODIUM

SMILES

[Na+].[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=C(O)C=C3)C([O-])=O

InChI

InChIKey=BYHDFCISJXIVBV-YWUHCJSESA-M
InChI=1S/C16H19N3O5S.Na/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7;/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24);/q;+1/p-1/t9-,10-,11+,14-;/m1./s1

HIDE SMILES / InChI
Amoxicillin is one of the widely prescribed antibacterial agents, which was discovered by scientists at Beecham Research Laboratories in 1972. In the US GlaxoSmithKline markets it under the original brand name Amoxil. It is the first line treatment for middle ear infections. It is also used for strep throat, pneumonia, skin infections, and urinary tract infections it is taken by mouth. Amoxicillin inhibits the third and final stage of bacterial cell wall synthesis by preferentially binding to specific penicillin-binding proteins (PBPs) that are located inside the bacterial cell wall. This results in a formation of defective cell wall and a cell death. Common side effects include nausea and rash. It may also increase the risk of yeast infections and, when used in combination with clavulanic acid, diarrhea. It should not be used in those who are allergic to penicillin.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

1980
Curative
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

1980
Curative
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

1980
Curative
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

1980
Curative
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

1980
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
11.8 μg/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXICILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
37.6 μg × h/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXICILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.5 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXICILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Disc. AE: Pharyngolaryngeal pain...
Other AEs: Nausea, Pharyngotonsillitis...
AEs leading to
discontinuation/dose reduction:
Pharyngolaryngeal pain (severe, 0.6%)
Other AEs:
Nausea (1.5%)
Pharyngotonsillitis (0.9%)
Vulvovaginal candidiasis (0.9%)
Headache (0.7%)
Diarrhea (0.5%)
Abdominal pain (0.5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 0.5%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Diarrhea 0.5%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Headache 0.7%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Pharyngotonsillitis 0.9%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Vulvovaginal candidiasis 0.9%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Nausea 1.5%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Pharyngolaryngeal pain severe, 0.6%
Disc. AE
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
2001
A prospective observational study of 5-, 7-, and 10-day antibiotic treatment for acute otitis media.
2001 Apr
Use of the t > MIC to choose between different dosing regimens of beta-lactam antibiotics.
2001 Apr
Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea.
2001 Apr
Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections.
2001 Apr
Effects of lansoprazole, clarithromycin and pH gradient on uptake of [14C]amoxycillin into rat gastric tissue.
2001 Apr
Helicobacter eradication versus prompt endoscopy for dyspepsia.
2001 Apr
Simultaneous determination of five beta-lactam antibiotics in bovine milk using liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
2001 Apr 1
Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection.
2001 Apr 1
Comparison of amoxicillin and azithromycin in the prevention of recurrent acute otitis media.
2001 Apr 6
Differentiation between reinfection and recrudescence of helicobacter pylori strains using PCR-based restriction fragment length polymorphism analysis.
2001 Feb
The effect of postsurgical antibiotics on the healing of intrabony defects following treatment with enamel matrix proteins.
2001 Feb
Bioequivalence study of a novel Solutab tablet formulation of amoxicillin/clavulanic acid versus the originator film-coated tablet.
2001 Feb
Sensitivity of Borrelia burgdorferi strains isolated in the Czech Republic.
2001 Feb
Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?
2001 Feb
Comparison of the efficacy and safety of different formulations of omeprazole-based triple therapies in the treatment of Helicobacter pylori-positive peptic ulcer.
2001 Feb
Early stage gastric MALT lymphoma with high-grade component cured by Helicobacter pylori eradication.
2001 Feb
Managing pneumonia in general practice.
2001 Feb
[Mechanism of drug resistance in Helicobacter pylori].
2001 Feb
[Usefulness of new triple therapy containing PPI].
2001 Feb
Free radical production by antibiotic-killed bacteria in the guinea pig middle ear.
2001 Feb
Acute generalized exanthematous pustulosis induced by amoxycillin with clavulanate.
2001 Feb
[Prevention of bacterial endocarditis in patients with prosthetic heart valves].
2001 Feb 15
Clostridium difficile--Associated diarrhea: A review.
2001 Feb 26
Improved phagocyte response by co-amoxiclav in renal transplant recipients.
2001 Feb 27
Definite streptococcus bovis endocarditis: characteristics in 20 patients.
2001 Jan
[Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities?].
2001 Jan
[Prevalence and treatment of Helicobacter pylori in gastro-duodenal ulcers. An experience in Liege].
2001 Jan
Antibiotic susceptibilities of Helicobacter pylori.
2001 Jan
[Pneumococcal antibiotic resistance. Results from 21 regional registries for 1999].
2001 Jan
[Pneumococcal antibiotic resistance in 1999. Results from 19 registries for 1999].
2001 Jan
[Pneumococcal antibiotic resistance. Data from 6 regional registries for 1999].
2001 Jan
Meropenem in neonatal severe infections due to multiresistant gram-negative bacteria.
2001 Jan
A prospective study of antibiotic use and associated infections in young children.
2001 Jan
[Prevention of endocarditis within the scope of ENT interventions. Current recommendations].
2001 Jan
[Prevalence of Moraxella catarrhalis colonization in asymptomatic carriers under 6 years of age].
2001 Jan-Feb
Charm Safe-Level beta-Lactam Test for amoxicillin, ampicillin, ceftiofur, cephapirin, and penicillin G in raw commingled milk.
2001 Jan-Feb
Clinical onset of the Crohn's disease after eradication therapy of Helicobacter pylori infection. Does Helicobacter pylori infection interact with natural history of inflammatory bowel diseases?
2001 Jan-Feb
Osseintegration following treatment of peri-implantitis and replacement of implant components. An experimental study in the dog.
2001 Mar
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
2001 Mar
A case of gastric plasmacytoma associated with Helicobacter pylori infection: improvement of abnormal endoscopic and EUS findings after H. pylori eradication.
2001 Mar
Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection.
2001 Mar
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate.
2001 Mar
Evaluation of the clinical microbiology profile of moxifloxacin.
2001 Mar 15
Tests for 2 x K contingency tables with clustered ordered categorical data.
2001 Mar 15
Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. ORACLE Collaborative Group.
2001 Mar 31
Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. ORACLE Collaborative Group.
2001 Mar 31
Simultaneous determination of amoxycillin and clavulanic acid in pharmaceutical dosage forms by LC with amperometric detection.
2001 May
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.
2001 May 15
Prospective evaluation of the impact of amoxicillin, clarithromycin and their combination on human gastrointestinal colonization by Candida species.
2001 May-Jun
Patents

Sample Use Guides

In adults, 750-1750 mg/day in divided doses every 8-12 hours. In Pediatric Patients > 3 Months of Age, 20-45 mg/kg/day in divided doses every 8-12 hours. Treatment of gonorrhea is 3 grams as a single oral dose. The upper dose for neonates and infants ≤ 3 months is 30 mg/kg/day divided every 12 hours. Dosing for H. pylori Infection: Triple therapy: 1 gram AMOXIL, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Dual therapy: 1 gram AMOXIL and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
AMOXICILLIN SODIUM
EP   MART.   USAN   WHO-DD  
USAN  
Official Name English
Amoxicillin sodium [WHO-DD]
Common Name English
BRL-2333AB-B
Code English
Amoxicillin (as the sodium salt)
Common Name English
AMOXICILLIN SODIUM SALT [MI]
Common Name English
AMOXICILLIN SODIUM [MART.]
Common Name English
SODIUM AMOXICILLIN
Common Name English
AMOXICILLIN SODIUM SALT
MI  
Common Name English
AMOXICILLIN SODIUM [EP MONOGRAPH]
Common Name English
AMOXICILLIN SODIUM [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1500
Created by admin on Fri Dec 15 15:33:20 GMT 2023 , Edited by admin on Fri Dec 15 15:33:20 GMT 2023
Code System Code Type Description
MERCK INDEX
m1844
Created by admin on Fri Dec 15 15:33:20 GMT 2023 , Edited by admin on Fri Dec 15 15:33:20 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL1082
Created by admin on Fri Dec 15 15:33:20 GMT 2023 , Edited by admin on Fri Dec 15 15:33:20 GMT 2023
PRIMARY
USAN
KK-95
Created by admin on Fri Dec 15 15:33:20 GMT 2023 , Edited by admin on Fri Dec 15 15:33:20 GMT 2023
PRIMARY
EPA CompTox
DTXSID80956137
Created by admin on Fri Dec 15 15:33:20 GMT 2023 , Edited by admin on Fri Dec 15 15:33:20 GMT 2023
PRIMARY
CAS
34642-77-8
Created by admin on Fri Dec 15 15:33:20 GMT 2023 , Edited by admin on Fri Dec 15 15:33:20 GMT 2023
PRIMARY
SMS_ID
100000090113
Created by admin on Fri Dec 15 15:33:20 GMT 2023 , Edited by admin on Fri Dec 15 15:33:20 GMT 2023
PRIMARY
ECHA (EC/EINECS)
252-124-1
Created by admin on Fri Dec 15 15:33:20 GMT 2023 , Edited by admin on Fri Dec 15 15:33:20 GMT 2023
PRIMARY
FDA UNII
544Y3D6MYH
Created by admin on Fri Dec 15 15:33:20 GMT 2023 , Edited by admin on Fri Dec 15 15:33:20 GMT 2023
PRIMARY
EVMPD
SUB00503MIG
Created by admin on Fri Dec 15 15:33:20 GMT 2023 , Edited by admin on Fri Dec 15 15:33:20 GMT 2023
PRIMARY
PUBCHEM
23663126
Created by admin on Fri Dec 15 15:33:20 GMT 2023 , Edited by admin on Fri Dec 15 15:33:20 GMT 2023
PRIMARY
NCI_THESAURUS
C72700
Created by admin on Fri Dec 15 15:33:20 GMT 2023 , Edited by admin on Fri Dec 15 15:33:20 GMT 2023
PRIMARY
CHEBI
51255
Created by admin on Fri Dec 15 15:33:20 GMT 2023 , Edited by admin on Fri Dec 15 15:33:20 GMT 2023
PRIMARY
DRUG BANK
DBSALT000868
Created by admin on Fri Dec 15 15:33:20 GMT 2023 , Edited by admin on Fri Dec 15 15:33:20 GMT 2023
PRIMARY
DAILYMED
544Y3D6MYH
Created by admin on Fri Dec 15 15:33:20 GMT 2023 , Edited by admin on Fri Dec 15 15:33:20 GMT 2023
PRIMARY
RXCUI
267360
Created by admin on Fri Dec 15 15:33:20 GMT 2023 , Edited by admin on Fri Dec 15 15:33:20 GMT 2023
PRIMARY RxNorm